Medtronic plc
MDT
Rank in Stocks
#183
Medtronic plc is a leading global medical technology enterprise that invents,... Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Share Price
$94.30
Market Cap
$120.63B
Change (1 day)
1.45%
Change (1 year)
-1.69%
Country
IE
Trade Medtronic plc (MDT)
Category
Healthcare
P/E ratio for Medtronic plc (MDT)
P/E ratio as of May 2026 TTM: 21.39
According to Medtronic plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 21.39. At the end of 2024 the company had a P/E ratio of 28.98.
P/E ratio history for Medtronic plc from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 21.39 | -8.48% |
| 2025 | 23.37 | -19.35% |
| 2024 | 28.98 | -9.95% |
| 2023 | 32.18 | 15.76% |
| 2022 | 27.80 | -43.06% |
| 2021 | 48.83 | 75.64% |
| 2020 | 27.80 | 9.46% |
| 2019 | 25.40 | -28.52% |
| 2018 | 35.53 | 24.91% |
| 2017 | 28.44 | -9.80% |
| 2016 | 31.53 | -0.78% |
| 2015 | 31.78 | 65.27% |
| 2014 | 19.23 | 40.13% |
| 2013 | 13.72 | 23.30% |
| 2012 | 11.13 | -23.39% |
| 2011 | 14.53 | -6.85% |
| 2010 | 15.60 | -5.77% |
| 2009 | 16.55 | -32.91% |
| 2008 | 24.67 | 13.60% |
| 2007 | 21.72 | -8.07% |
| 2006 | 23.62 | -33.21% |
| 2005 | 35.37 | 13.16% |
| 2004 | 31.26 | -13.97% |
| 2003 | 36.33 | -33.97% |
| 2002 | 55.03 | 7.28% |
| 2001 | 51.29 | -9.73% |
| 2000 | 56.83 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 33.11 | 54.80% |
US
|
|
| 28.94 | 35.33% |
US
|
|
| 17.34 | -18.93% |
US
|
|
| - | - |
DE
|
|
| 49.68 | 132.30% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.